9. SEGMENT REPORTING (Tables)

9 Months Ended

Jan. 31, 2015

Segment Reporting [Abstract]

Segment information

	Three Months Ended January 31,						Nine Months Ended January 31,
	2015			2014			2015			2014
Contract manufacturing services revenue	$	5,677,000		$	3,885,000		$	17,436,000		$	15,820,000
Cost of contract manufacturing services		3,113,000			2,416,000			10,835,000			9,281,000
Gross profit		2,564,000			1,469,000			6,601,000			6,539,000
Revenue from products in research and development		–			–			37,000			107,000
Research and development expense		(11,261,000	)		(6,649,000	)		(31,465,000	)		(18,910,000	)
Selling, general and administrative expense		(4,325,000	)		(4,563,000	)		(13,503,000	)		(12,913,000	)
Other income, net		28,000			19,000			107,000			63,000
Net loss	$	(12,994,000	)	$	(9,724,000	)	$	(38,223,000	)	$	(25,114,000	)

Customer Revenue

	Three Months Ended January 31,				Nine Months Ended January 31,
	2015		2014		2015		2014
Halozyme Therapeutics, Inc.		81%		87%		84%		88%
Advanced BioScience Laboratories, Inc.		4		13		10		9
Other customers		15		–		6		3
Total		100%		100%		100%		100%

Long Lived Assets

	January 31, 2015		April 30, 2014
Long-lived Assets, net:
Contract manufacturing services	$	6,701,000	$	1,956,000
Products in research and development		2,257,000		491,000
Total	$	8,958,000	$	2,447,000